PSP Research LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 6, 2026), PSP Research LLC reported 85 stock positions worth $114.4 million. Its top holding was iShares 0-3 Month Treasury B (SGOV) at 61.4% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 0.5%) and Travere Therapeutics (TVTX, 0.5%).
- Most Recent 13F
- Q2 2026
- Location
- LAS VEGAS, NV
- CIK
- 0002106939
- Portfolio Value
- $114.4M (Q4 2025)
- SEC Filing
- 0001951757-26-000380 ↗ filed Feb 6, 2026
Holdings Value
Holdings 85 stocks · $114.4M
| SGOV iShares 0-3 Month Treasury B | 61.41% | 700,000 | $70.3M | — |
| PRAX Praxis Precision Medicines I | 0.51% | 1,982 | $584K | — |
| TVTX Travere Therapeutics Inc. | 0.51% | 15,272 | $584K | — |
| TYRA Tyra Biosciences Inc. | 0.50% | 21,853 | $575K | — |
| PHVS Pharvaris NV | 0.50% | 20,511 | $569K | — |
| JAZZ Jazz Pharmaceuticals PLC | 0.48% | 3,258 | $554K | — |
| CLDX Celldex Therapeutics Inc. | 0.48% | 20,368 | $553K | — |
| CGON CG Oncology Inc. | 0.48% | 13,293 | $552K | — |
| BLTE Belite Bio Inc. - ADR | 0.48% | 3,443 | $551K | — |
| ASND Ascendis Pharma A/S | 0.48% | 2,579 | $550K | — |
| APLS Apellis Pharmaceuticals Inc. | 0.48% | 21,866 | $549K | — |
| TERN Terns Pharmaceuticals Inc. | 0.48% | 13,560 | $548K | — |
| RVMD Revolution Medicines Inc. | 0.48% | 6,872 | $547K | — |
| CNTA Centessa Pharmaceuticals Ltd. | 0.48% | 21,879 | $547K | — |
| BBIO Bridgebio Pharma Inc. | 0.48% | 7,140 | $546K | — |
| NRIX Nurix Therapeutics Inc. | 0.48% | 28,713 | $545K | — |
| ARQT Arcutis Biotherapeutics Inc. | 0.47% | 18,716 | $544K | — |
| KOD Kodiak Sciences Inc. | 0.47% | 19,418 | $543K | — |
| IMNM Immunome Inc. | 0.47% | 25,245 | $542K | — |
| AUPH Aurinia Pharmaceuticals Inc. | 0.47% | 33,953 | $542K | — |
| MIRM Mirum Pharmaceuticals Inc. | 0.47% | 6,854 | $541K | — |
| HALO Halozyme Therapeutics Inc. | 0.47% | 8,026 | $540K | — |
| EYPT Eyepoint Inc. | 0.47% | 29,530 | $540K | — |
| ALKS Alkermes PLC | 0.47% | 19,280 | $539K | — |
| IONS Ionis Pharmaceuticals Inc. | 0.47% | 6,800 | $538K | — |
| MLYS Mineralys Therapeutics Inc. | 0.47% | 14,818 | $538K | — |
| ACLX Arcellx Inc. | 0.47% | 8,224 | $536K | — |
| PTCT PTC Therapeutics Inc. | 0.47% | 7,046 | $535K | — |
| ZYME Zymeworks Inc. | 0.47% | 20,312 | $535K | — |
| SUPN Supernus Pharmaceuticals Inc. | 0.47% | 10,758 | $535K | — |
| PTGX Protagonist Therapeutics Inc. | 0.47% | 6,121 | $535K | — |
| HRMY Harmony Biosciences Holdings | 0.47% | 14,283 | $534K | — |
| ROIV Roivant Sciences Ltd. | 0.47% | 24,621 | $534K | — |
| RPRX Royalty Pharma PLC Class A | 0.47% | 13,826 | $534K | — |
| AMLX Amylyx Pharmaceuticals Inc. | 0.47% | 44,223 | $534K | — |
| LQDA Liquidia Corp. | 0.47% | 15,485 | $534K | — |
| TARS Tarsus Pharmaceuticals Inc. | 0.47% | 6,519 | $534K | — |
| PVLA Palvella Therapeutics Inc. | 0.47% | 5,084 | $532K | — |
| RAPP Rapport Therapeutics Inc. | 0.46% | 17,506 | $531K | — |
| TGTX TG Therapeutics Inc. | 0.46% | 17,807 | $531K | — |
| INSM Insmed Inc. | 0.46% | 3,049 | $531K | — |
| LEGN Legend Biotech Corp.-ADR | 0.46% | 24,397 | $530K | — |
| ARGX Argenx SE - ADR | 0.46% | 630 | $530K | — |
| NBIX Neurocrine Biosciences Inc. | 0.46% | 3,734 | $530K | — |
| NUVL Nuvalent Inc. Class A | 0.46% | 5,261 | $529K | — |
| INCY Incyte Corp. | 0.46% | 5,350 | $528K | — |
| CYTK Cytokinetics Inc. | 0.46% | 8,313 | $528K | — |
| VRDN Viridian Therapeutics Inc. | 0.46% | 16,967 | $528K | — |
| ACAD Acadia Pharmaceuticals Inc. | 0.46% | 19,766 | $528K | — |
| WVE Wave Life Sciences Ltd. | 0.46% | 31,040 | $528K | — |
| STOK Stoke Therapeutics Inc. | 0.46% | 16,621 | $528K | — |
| APGE Apogee Therapeutics Inc. | 0.46% | 6,984 | $527K | — |
| CRNX Crinetics Pharmaceuticals Inc. | 0.46% | 11,316 | $527K | — |
| UTHR United Therapeutics Corp. | 0.46% | 1,080 | $526K | — |
| MAZE Maze Therapeutics Inc. | 0.46% | 12,672 | $525K | — |
| DNTH Dianthus Therapeutics Inc. | 0.46% | 12,725 | $524K | — |
| DNLI Denali Therapeutics Inc. | 0.46% | 31,762 | $524K | — |
| ALNY Alnylam Pharmaceuticals Inc. | 0.46% | 1,318 | $524K | — |
| EXEL Exelixis Inc. | 0.46% | 11,948 | $524K | — |
| XENE Xenon Pharmaceuticals Inc. | 0.46% | 11,678 | $523K | — |
| NAMS Newamsterdam Pharma Co. NV | 0.46% | 14,920 | $523K | — |
| CELC Celcuity Inc. | 0.46% | 5,244 | $523K | — |
| KNSA Kiniksa Pharmaceuticals Inte | 0.46% | 12,655 | $522K | — |
| BMRN Biomarin Pharmaceutical Inc. | 0.46% | 8,772 | $521K | — |
| OCUL Ocular Therapeutix Inc. | 0.45% | 42,853 | $520K | — |
| MDGL Madrigal Pharmaceuticals Inc. | 0.45% | 892 | $519K | — |
| SNDX Syndax Pharmaceuticals Inc. | 0.45% | 24,716 | $519K | — |
| SYRE Spyre Therapeutics Inc. | 0.45% | 15,840 | $519K | — |
| VKTX Viking Therapeutics Inc. | 0.45% | 14,714 | $518K | — |
| IMVT Immunovant Inc. | 0.45% | 20,305 | $516K | — |
| BEAM Beam Therapeutics Inc. | 0.44% | 18,334 | $508K | — |
| RYTM Rhythm Pharmaceuticals Inc. | 0.44% | 4,738 | $507K | — |
| VERA Vera Therapeutics Inc. | 0.44% | 9,996 | $506K | — |
| INBX Inhibrx Biosciences Inc. | 0.44% | 6,389 | $505K | — |
| CRSP Crispr Therapeutics AG | 0.44% | 9,580 | $502K | — |
| IMCR Immunocore Holdings PLC-ADR | 0.44% | 14,424 | $501K | — |
| KYMR Kymera Therapeutics Inc. | 0.43% | 6,348 | $494K | — |
| UPB Upstream Bio Inc. | 0.42% | 17,634 | $479K | — |
| OLMA Olema Pharmaceuticals Inc. | 0.42% | 19,063 | $477K | — |
| COGT Cogent Biosciences Inc. | 0.41% | 13,233 | $470K | — |
| GPCR Structure Therapeutics Inc. | 0.41% | 6,719 | $467K | — |
| MIND MEDICINE MINDMED INC | 0.41% | 34,841 | $467K | — |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.39% | 6,689 | $444K | — |
| ALMS Alumis Inc. | 0.37% | 43,769 | $427K | — |
| DYN Dyne Therapeutics Inc. | 0.37% | 21,535 | $421K | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.